FDA approves Protalix's (PLX) Gaucher Disease drug Elelyso
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Join SI Premium – FREE
The FDA approved Protalix's (NYSE: PLX) Gaucher Disease drug Elelyso
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca halts Phase III lung cancer trial after data review
- EMA validates Pfizer and Valneva's Lyme disease vaccine application
- Propanc Biopharma begins prep for Phase 1b cancer therapy trial in Australia
Create E-mail Alert Related Categories
FDA, Hot FDA NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
